Yair Lotan mainly focuses on Bladder cancer, Surgery, Internal medicine, Cystectomy and Urology. His Bladder cancer study combines topics in areas such as Stage, Urinary bladder and Carcinoma, Pathology. His work carried out in the field of Surgery brings together such families of science as Lymphadenectomy, Intensive care medicine, Nomogram, Nephrectomy and Disease.
His Internal medicine study incorporates themes from Gynecology and Oncology. As part of one scientific family, Yair Lotan deals mainly with the area of Cystectomy, narrowing it down to issues related to the Neoadjuvant therapy, and often Chemotherapy. His studies deal with areas such as Lymphovascular invasion, Carcinoma in situ, Urine cytology, Biopsy and TNM staging system as well as Urology.
Yair Lotan mainly investigates Internal medicine, Bladder cancer, Oncology, Urology and Surgery. He works in the field of Bladder cancer, namely Cystectomy. His research in Oncology intersects with topics in Tissue microarray, Chemotherapy, Cohort and Hazard ratio.
Yair Lotan combines subjects such as Lymphovascular invasion, Carcinoma in situ, Carcinoma, Transitional cell carcinoma and Proportional hazards model with his study of Urology. Yair Lotan regularly ties together related areas like Nephrectomy in his Surgery studies. Cancer research is closely connected to Pathology in his research, which is encompassed under the umbrella topic of Cancer.
His primary scientific interests are in Bladder cancer, Internal medicine, Oncology, Urology and Cystectomy. Yair Lotan works mostly in the field of Bladder cancer, limiting it down to concerns involving Cystoscopy and, occasionally, Cytology and Prospective cohort study. His research on Internal medicine often connects related topics like Gastroenterology.
His Oncology research includes elements of Stage, Metastatic Urothelial Carcinoma, Disease and Immunotherapy. His Urology research is multidisciplinary, incorporating elements of Carcinoma in situ, Urine, Prostate and Prostate cancer. His Cystectomy research is multidisciplinary, relying on both Basal, Clinical trial and Cohort.
His main research concerns Bladder cancer, Internal medicine, Cystectomy, Oncology and Urology. His research integrates issues of Flexible cystoscopy, Cystoscopy, Lymphovascular invasion and Clinical trial in his study of Bladder cancer. His work on Internal medicine deals in particular with Cancer, Disease, Retroperitoneal lymph node dissection, Immunohistochemistry and Carcinoma.
His Cystectomy study combines topics from a wide range of disciplines, such as Chemotherapy, Induction chemotherapy, Cohort, Retrospective cohort study and Concomitant. The various areas that Yair Lotan examines in his Oncology study include Basal, Chemotherapy naive, Hazard ratio, Survival analysis and Human genetics. His Urology research integrates issues from Neoadjuvant therapy, Carcinoma in situ, Survival rate, Extraprostatic extension and Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular characterization of urothelial bladder carcinoma
John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang.
Epidemiology and risk factors of urothelial bladder cancer
Maximilian Burger;James W.F. Catto;Guido Dalbagni;H. Barton Grossman.
European Urology (2013)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson;Jaegil Kim;Hikmat Al-Ahmadie;Joaquim Bellmunt.
Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
Vitaly Margulis;Shahrokh F. Shariat;Surena F. Matin;Ashish M. Kamat.
Systematic review of complications of prostate biopsy.
Stacy Loeb;Annelies Vellekoop;Hashim U. Ahmed;James Catto.
European Urology (2013)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Peña-Llopis;Silvia Vega-Rubín-De-Celis;Silvia Vega-Rubín-De-Celis;Arnold Liao;Nan Leng.
Nature Genetics (2012)
Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium
Shahrokh F. Shariat;Pierre I. Karakiewicz;Ganesh S. Palapattu;Yair Lotan.
The Journal of Urology (2006)
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
Bas W.G. van Rhijn;Maximilian Burger;Yair Lotan;Eduardo Solsona.
European Urology (2009)
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses
Yair Lotan;Claus G Roehrborn.
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
Sam S. Chang;Bernard H. Bochner;Roger Chou;Robert Dreicer.
The Journal of Urology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: